Automatic Web Traffic Generator

Norepinephrine Depletion in Idiopathic Orthostatic Hypotension

HERMES A. KONTOS, M.D., Ph.D., F.A.C.P.; DAVID W. RICHARDSON, M.D., F.A.C.P.; JOHN E. NORVELL, Ph.D. Five patients with idiopathic orthostatic hypotension and defective vasoconstrictor responses to th... read more

Additional Analysis Confirms Significant Symptomatic Benefit of Droxidopa in Treatment of Neurogenic Orthostatic Hypotension

Additional Analysis Confirms Significant Symptomatic Benefit of Droxidopa in ... Neurogenic Orthostatic Hypotension ... and tolerability of Droxidopa for the treatment of neurogenic orthostatic ... read more

Chelsea Therapeutics (CHTP) Confirms FDA Approval of NORTHERA

Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) confirmed that the FDA granted accelerated approval of NORTHERATM (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotensio... read more

Chelsea announces first patient dosed in NORTHERA study 401

an orally active synthetic precursor of norepinephrine, being studied for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure, dopamine beta hydr... read more

Urinary Catecholamine Metabolites Distinguish Different Types of Sympathetic Neuronal Dysfunction in Patients with Orthostatic Hypotension

Urinary excretion rates of the major norepinephrine metabolites ... subjects and 23 patients with neurogenic orthostatic hypotension due to either multiple system atrophy [Shy-Drager Dyndrome (MSA)] o... read more

Is Chelsea Therapeutics A Buy After Skyrocketing Up Over 150%?

By increasing the supply of norepinephrine available for delivery to its receptors, droxidopa may improve orthostatic blood pressure and alleviate symptoms of orthostatic hypotension ... as dopamine b... read more

Chelsea Announces Publication of Clinical Autonomic Research Supplement Focusing On Neurogenic Orthostatic Hypotension

"By highlighting the causes, severity and prevalence of neurogenic orthostatic hypotension ... release of norepinephrine, the neurotransmitter used by sympathetic autonomic nerves to send signals to t... read more

Droxidopa for Symptomatic Neurogenic Hypotension

synthetic amino acid precursor of norepinephrine that received accelerated Food and Drug Administration approval in February 2014 after Orphan Drug status for a debilitating condition known as symptom... read more

US FDA grants priority review status for Chelsea's Northera NDA for symptomatic NOH treatment

for Northera (droxidopa), an orally active synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary autonomic failure ( ... read more

Diabetes sparks a rise in neuropathy

Others who should do so include people with vitamin deficiency ... For autonomic neuropathy, medications can be used to help regulate the bodily functions that are no longer working as they should, su... read more

Chelsea Therapeutics Announces FDA Advisory Committee Meeting Date for Review of NORTHERA(TM) NDA for the Treatment of Symptomatic NOH

Northera is an orally active synthetic precursor of norepinephrine ... orthostatic hypotension (NOH) in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy and pure a... read more

Chelsea announces positive results from combined Northera data phase III trials in Neurogenic OH patients

The results, which include data from over 250 patients with symptomatic Neurogenic OH and diagnoses of Parkinson's disease, multiple system atrophy (MSA), pure autonomic failure (PAF), dopamine beta h... read more